register | login
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2022 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Rituximab

Novel first-line treatment option for mantle cell lymphoma 

Presented By
Prof. Michael Wang, Anderson Cancer Center, TX, USA
Trial
Phase 3, SHINE
Conference
ASCO 2022

5 August, 2022 14:30

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Presented By
Prof. Ulrich Specks, Mayo Clinic, MN, USA
Trial
Phase 3, ADVOCATE
Conference
ATS 2022

18 July, 2022 11:56

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA
Trial
Cohort study, RE-MIND2
Conference
ASH 2021

4 February, 2022 11:08

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By
Prof. Hervé Tilly, University of Rouen, France
Trial
Phase 3, POLARIX
Conference
ASH 2021

4 February, 2022 10:56

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert
Dr Jennifer Woyach, Ohio State University, OH, USA
Trial
Phase 3, Alliance A041202
Conference
ASH 2021

3 February, 2022 23:22

Vaccine booster improves immune response in patients treated with rituximab

Presented By
Prof. Michael Bonelli, Medical University of Vienna, Austria
Conference
ACR 2021

14 January, 2022 11:07

Ultra-low dosing of rituximab in RA is a viable treatment option

Presented By
Mr Nathan den Broeder, Sint Maartenskliniek, the Netherlands
Trial
REDO
Conference
ACR 2021

14 January, 2022 10:58

Sequential rituximab after belimumab does not improve disease control in SLE

Presented By
Prof. Cynthia Aranow, Feinstein Institutes for Medical Research, NY, USA
Trial
Phase 3, BLISS-BELIEVE
Conference
ACR 2021

14 January, 2022 10:02

ASH 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASH 2021

4 January, 2022 08:00

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By
Mr Peter Alping, Karolinska Institutet, Sweden
Trial
Phase 4, COMBAT-MS
Conference
ECTRIMS 2021

9 December, 2021 14:36

MS patients at risk of hampered immune response after vaccination

Presented By
Prof. Maria Pia Sormani, University of Genoa, Italy
Conference
ECTRIMS 2021

9 December, 2021 10:49

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By
Dr Steve Simpson-Yap, University of Melbourne, Australia
Conference
ECTRIMS 2021

9 December, 2021 10:41

Acquired TTP: new treatments and updated guidelines

Presented By
Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain
Trial
HERCULES; TITAN
Conference
EHA 2021

5 August, 2021 15:25

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By
Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands
Trial
Phase 2, HOVON 139/GiVe
Conference
EHA 2021

5 August, 2021 13:38

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By
Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany
Trial
Phase 2, IELSG32
Conference
EHA 2021

5 August, 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By
Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA
Conference
EHA 2021

5 August, 2021 11:55

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By
Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany
Conference
EULAR 2021

2 August, 2021 23:53

Rituximab or JAK inhibitors increase the risk of severe COVID-19

Presented By
Dr Jeffrey Sparks, Brigham and Women’s Hospital, MA, USA
Conference
EULAR 2021

2 August, 2021 23:36

Updates on COVID-19 vaccines in patients with rheumatic disease

Presented By
Dr Victoria Furer, Tel Aviv Sourasky Medical Center, Israel
Conference
EULAR 2021

2 August, 2021 22:44

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By
Mr Andrei Barbulescu, Karolinska Institutet, Sweden
Conference
EULAR 2021

2 August, 2021 10:23

MS therapies influence COVID-19 severity

Conference
AAN 2021

16 June, 2021 11:42

Remission with rituximab in refractory generalised myasthenia gravis

Conference
AAN 2021

16 June, 2021 11:39

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?

Presented By
Dr Steve Simpson-Yap, Melbourne School of Population and Global Health, Australia
Journal
Physician’s Weekly
Conference
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April, 2021 16:27

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By
Prof. Joan Bathon, Columbia University, USA
Conference
ACR 2020

18 January, 2021 10:59

Poor disease control: a risk factor for severe COVID-19

Presented By
Prof. Rebecca Grainger, University of Otago, New Zealand
Trial
COVID-19 Global Rheumatology Alliance Registry
Conference
ACR 2020

18 January, 2021 10:57

Lupus nephritis: new therapies on the horizon in 2020

Presented By
Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA
Conference
ACR 2020

18 January, 2021 10:54

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference
MS Virtual 2020

25 November, 2020 17:09

Low-dose rituximab as effective as high-dose, but safer

Conference
MS Virtual 2020

25 November, 2020 16:57

Efficacy and safety of rituximab in refractory MG corroborated

Presented By
Dr A Dos Santos, University Hospital of Nantes, France
Conference
EAN 2020

10 September, 2020 14:24

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By
Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA
Conference
EAN 2020

10 September, 2020 12:17

Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis

Presented By
Dr Rona Smith, University of Cambridge, UK
Trial
RITAZAREM
Conference
ACR 2019

4 February, 2020 23:18

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By
Dr Evelyne Vinet, McGill University, Montreal, Canada
Conference
ACR 2019

4 February, 2020 23:12

Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration

Presented By
Prof. Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, UK
Conference
ACR 2019

4 February, 2020 20:10

Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Presented By
Prof. Pascal Joly, Rouen University Hospital, France
Trial
Phase 3, PEMPHIX, Ritux 3
Conference
EADV 2019

9 December, 2019 19:52

Risk of hypogammaglobulinemia and rituximab

Presented By
Dr Susanna Hallberg, Karolinska Institute, Sweden
Conference
ECTRIMS 2019

8 November, 2019 21:18

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By
Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy
Trial
Phase 3, ASCEND
Conference
EHA 2019

9 August, 2019 15:28

Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials

Trial
MAGNIFY, AUGMENT
Conference
ASCO 2019

15 July, 2019 14:17

Promising results rituximab in systemic sclerosis, and systemic lupus erythematosus classification criteria

Presented By
Prof. Allanore, University of Paris Descartes University, France
Conference
EULAR 2018

24 August, 2018 22:49

Combining new drugs with different mechanisms

Trial
EXPLORER
Conference
ECCO 2018

28 May, 2018 23:31
site created by:   

© 2021 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT